Results 221 to 230 of about 76,815 (259)
Some of the next articles are maybe not open access.
Current Opinion in Hematology, 1996
Attention is being directed at increasing the intensity of therapy as a means of improving the results of primary therapy for non-Hodgkin's lymphoma. There is increasing evidence that the use of high-dose consolidation therapy followed by autologous hematopoietic rescue in first remission improves survival in high-risk patients.
P J, Bierman, J O, Armitage
openaire +2 more sources
Attention is being directed at increasing the intensity of therapy as a means of improving the results of primary therapy for non-Hodgkin's lymphoma. There is increasing evidence that the use of high-dose consolidation therapy followed by autologous hematopoietic rescue in first remission improves survival in high-risk patients.
P J, Bierman, J O, Armitage
openaire +2 more sources
Current Problems in Cancer, 1996
Lymphoid neoplasia is a complex area comprising multiple diseases with varied pathology, treatment, and outcome. The non-Hodgkin's lymphomas are reviewed here. Non-Hodgkin's lymphomas, collectively, represent the sixth most common cancer in the United States as well as the sixth most common cause of cancer deaths. The overall incidence of non-Hodgkin's
openaire +2 more sources
Lymphoid neoplasia is a complex area comprising multiple diseases with varied pathology, treatment, and outcome. The non-Hodgkin's lymphomas are reviewed here. Non-Hodgkin's lymphomas, collectively, represent the sixth most common cancer in the United States as well as the sixth most common cause of cancer deaths. The overall incidence of non-Hodgkin's
openaire +2 more sources
Classification of Non-Hodgkin's Lymphoma
Hematology/Oncology Clinics of North America, 2008This article provides an overview of the pathology and classification of non-Hodgkin lymphomas. Key histologic features are described for the common entities including both B-cell and T/NK-cell lineages. Additionally, details of the characteristic immunophenotypic findings, molecular genetic results, and common or clinically relevant cytogenetic ...
David J, Good, Randy D, Gascoyne
openaire +2 more sources
Non-Hodgkin lymphoma: an update
The Lancet Oncology, 2004Non-Hodgkin lymphoma (NHL) causes many deaths worldwide, and its incidence is increasing. Although some cases are associated with immunodeficiency, autoimmunity, or viral infections, in most cases the causes of NHL are not understood. However, there have been some important advances in our understanding of the development of healthy lymphocytes and the
Bryan T, Hennessy +2 more
openaire +2 more sources
Immunopathology of non-Hodgkin lymphomas
Klinische Wochenschrift, 1984The immunopathological features of lymphocytic non-Hodgkin lymphomas (NHL), follicular centre cell tumours and "large-cell" NHL are described with particular emphasis on in situ evaluation of cryostat sections using monoclonal antibodies. The immunological phenotypes of tumour cells and the pattern of "reactive" cellular infiltrates with characteristic
H, Huber +3 more
openaire +2 more sources
Gastrointestinal Non-Hodgkin's Lymphoma
Leukemia & Lymphoma, 1991The records of 77 patients with gastrointestinal Non-Hodgkin's Lymphoma (GI-NHL) diagnosed from 1972 to 1988 were reviewed. There were 47 male and 30 female patients, median age 56 years (range 20-82 years). Twenty-four patients had stage I disease at presentation, 25 stage II, 8 stage III and 20 stage IV.
A K, Stewart +5 more
openaire +2 more sources
Radioimmunotherapy of Non-Hodgkins Lymphomas
Current Drug Targets, 2003Enthusiasm for the use of monoclonal antibodies, such as rituximab, has markedly changed the approach to patients with non-Hodgkin lymphomas (NHLs). Nevertheless, more effective therapies are needed. Radioimmunotherapy as a form of targeted radiation therapy may add significantly to our therapeutic options.
openaire +3 more sources
Non-Hodgkin's lymphoma of the thyroid
Clinical Radiology, 1987Twenty-eight patients with non-Hodgkin's lymphoma of the thyroid were treated between 1954 and 1981. The duration of follow-up ranged from 39 to 176 months. The overall 5 year survival was 51%. Twenty deaths have been recorded of which 12 were attributed to non-Hodgkin's lymphoma. Eight patients relapsed following initial treatment.
A R, Makepeace +2 more
openaire +2 more sources
Endobronchial Non-Hodgkin's Lymphoma
Chest, 1983Four patients with endobronchial non-Hodgkin's lymphoma are presented. Although endobronchial Hodgkin's disease is not uncommon, endobronchial non-Hodgkin's lymphoma is extremely rare. All patients had disseminated disease at the time of their endobronchial involvement. Chest radiographs revealed hilar masses and/or varying degrees of lobar collapse in
Terry L. Kilgore +2 more
openaire +2 more sources